Adragos Pharma, Prange Group Acquires Fresenius Kabi Plant


The purchase boosts the parties’ sterile liquid manufacturing capabilities.

Image Credit: Adobe Stock Images/

Image Credit: Adobe Stock Images/

The Prange Group, who invests in rising pharma companies, and its affiliate Adragos Pharma, a European contract development and manufacturing organization (CDMO), has officially acquired Fresenius Kabi’s sterile pharmaceutical manufacturing unit Halden, Norway.

Although details surrounding the deal were not revealed, this purchase helps grow both parties’ global presence by adding significant capacity for this particular type of production. Using blow-fill-seal technology for the production ampoules and vials, the Halden site produces sterile liquids for the Nordic market, along with over 70 countries.

“We appreciate Fresenius Kabi for trusting in our group as being the right partner for building the future of the Halden site,” noted Otto Prange, chairman and owner of the Prange Group. “Together with the experienced Halden team, we will introduce new customers who can rely as well as Fresenius and the other big pharma customers on our full commitment for reliable, global supply.”

Dr. Andreas Raabe, Adragos Pharma’s CEO, also sees the benefits of the new deal, particularly for its supply chain benefits.

“In joining forces with Prange Group,” he said, “we’re strategically advancing towards a shared commitment to deliver quality and reliability on a global scale, benefitting both customers and patients. This acquisition is set to unlock new potential, amplifying the site’s capabilities, and showcasing the remarkable expertise of its dedicated workforce. Through the acquisition, we aim to foster growth and innovation.”


1. One of Northern Europe’s Largest Production Sites Successfully Taken Over by the Prange Group and Adragos Pharma. Adragos Pharma. News release. March 1, 2024. Accessed March 4, 2024.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.